IL4 and peripheral arterial disease: Although IL‐13 upregulation is reported [7], the broader immunomodulatory effects of JAK inhibitors may better address the immune dysregulation specific to PAD, compared to the more selective IL‐4/IL‐13 inhibition provided by dupilumab [3].